GSK sells rare disease gene therapy portfolioFinancial TimesGlaxoSmithKline has offloaded its rare disease gene therapy portfolio to the biotechnology company Orchard Therapeutics, in exchange for a near-20 per cent stake in the two-year-old business. … Continue reading
WHTCGSK divests rare disease gene therapy drugs to Orchard TherapeuticsWHTCFILE PHOTO: The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. REUTERS/Loriene Perera/File Photo. LONDON (Reuters) – GlaxoSmithKline s… Continue reading
PharmaTimes |
GSK divests rare disease gene therapy drugs to Orchard Therapeutics
Reuters LONDON, April 12 (Reuters) – GlaxoSmithKline said on Thursday is was transferring its rare disease gene therapy drugs to Orchard Therapeutics as Chief Executive Emma Walmsley makes good on her promise to prune the drugmaker’s pharmaceuticals portfolio … GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard TherapeuticsGlobeNewswire (press release) GSK hands rare disease gene therapies over to OrchardPharmaTimes |
Asbarez Armenian News |
ABMDR Donor’s Stem Cells Rushed to Iran for Life-Saving Transplant
Asbarez Armenian News LOS ANGELES—On April 10, stem cells donated by Dr. Georgi Iloyan, of Yerevan, were dispatched to Iran, to be used for a life-saving transplant. The person for whom the stem cells were donated is a young patient in Tehran who suffers from leukemia. The … |